Summary
Breast cancer (BC) is a prevalent kind of cancer worldwide and it is one of the primary causes of cancer-related deaths in women. The research has shown that early detection of BC could significantly increase the chances of survival for patients. Recently, there has been a growing interest in microRNAs (miRNAs) as potential biomarkers for the early diagnosis of BC. Therefore, the development of new diagnostic tools for the early detection of BC is necessary. Thus, biosensors based on DNA nanotechnology emerge as a novel, versatile, and easily accessible alternative.
In this context, the synergy between the fluorescence properties of DNA/AgNCs and the structural properties of DNA-origami will allow the creation of a new generation of hybrid nanomaterials (nanohybrids), which could be conceived as biosensors for the detection of miRNAs associated to BC with high sensitivity, sequence specificity, high throughput, low cost, and easy access.
ODASMIR aims to design origami-DNA/AgNCs nanohybrids (ODAs) to develop a biosensor to diagnose BC through the detection of different miRNAs and, it will validate in in vitro models (2D and 3D). ODASMIR presents a multidisciplinary approach, both the objectives and the experimental methodology are on the interface between biology and chemistry. The biosensors obtained and their validation at the clinical level could have a significant impact on the accurate and early diagnosis of BC representing a significant advance in the field of nanomedicine.
In this context, the synergy between the fluorescence properties of DNA/AgNCs and the structural properties of DNA-origami will allow the creation of a new generation of hybrid nanomaterials (nanohybrids), which could be conceived as biosensors for the detection of miRNAs associated to BC with high sensitivity, sequence specificity, high throughput, low cost, and easy access.
ODASMIR aims to design origami-DNA/AgNCs nanohybrids (ODAs) to develop a biosensor to diagnose BC through the detection of different miRNAs and, it will validate in in vitro models (2D and 3D). ODASMIR presents a multidisciplinary approach, both the objectives and the experimental methodology are on the interface between biology and chemistry. The biosensors obtained and their validation at the clinical level could have a significant impact on the accurate and early diagnosis of BC representing a significant advance in the field of nanomedicine.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101153417 |
| Start date: | 01-09-2024 |
| End date: | 31-08-2026 |
| Total budget - Public funding: | - 181 152,00 Euro |
Cordis data
Original description
Breast cancer (BC) is a prevalent kind of cancer worldwide and it is one of the primary causes of cancer-related deaths in women. The research has shown that early detection of BC could significantly increase the chances of survival for patients. Recently, there has been a growing interest in microRNAs (miRNAs) as potential biomarkers for the early diagnosis of BC. Therefore, the development of new diagnostic tools for the early detection of BC is necessary. Thus, biosensors based on DNA nanotechnology emerge as a novel, versatile, and easily accessible alternative.In this context, the synergy between the fluorescence properties of DNA/AgNCs and the structural properties of DNA-origami will allow the creation of a new generation of hybrid nanomaterials (nanohybrids), which could be conceived as biosensors for the detection of miRNAs associated to BC with high sensitivity, sequence specificity, high throughput, low cost, and easy access.
ODASMIR aims to design origami-DNA/AgNCs nanohybrids (ODAs) to develop a biosensor to diagnose BC through the detection of different miRNAs and, it will validate in in vitro models (2D and 3D). ODASMIR presents a multidisciplinary approach, both the objectives and the experimental methodology are on the interface between biology and chemistry. The biosensors obtained and their validation at the clinical level could have a significant impact on the accurate and early diagnosis of BC representing a significant advance in the field of nanomedicine.
Status
SIGNEDCall topic
HORIZON-MSCA-2023-PF-01-01Update Date
25-11-2024
Images
No images available.
Geographical location(s)
